Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Nayar R, Barkan GA, Benedict C, Booth C, Chhieng DC, Mody D, et al. Laboratory management curriculum for cytopathology subspecialty training. J Am Soc Cytopathol. 2018;7(2):61-78.

Ooki A, Dinalankara W, Marchionni L, Tsay J-, Goparaju C, Maleki Z, et al. Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma. Oncogene. 2018;37(45):5967-5981.

Orleans RA, Magro CM, Varghese GI. A case of granuloma annulare mimicking tinea cruris. Dermatol Online J. 2018;24(8).

Mavragani CP, Nezos A, Sagalovskiy I, Seshan S, Kirou KA, Crow MK. Defective regulation of L1 endogenous retroelements in primary Sjogren's syndrome and systemic lupus erythematosus: Role of methylating enzymes. J Autoimmun. 2018;88:75-82.

Al-Tamari HM, Dabral S, Schmall A, Sarvari P, Ruppert C, Paik J, et al. FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis. EMBO Mol Med. 2018;10(2):276-293.

Gafeer MM, Mohammed KH, Ormenisan-Gherasim C, Choudhary F, Siddiqui MT, Cohen C. Diagnostic Utility of PD-L1 Expression in Lung Adenocarcinoma: Immunohistochemistry and RNA In Situ Hybridization. Appl Immunohistochem Mol Morphol. 2018;26(8):e86-e90.

Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, et al. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer. 2018;124(5):1008-1015.

Truong TH, Hu H, Temiz NA, Hagen KM, Girard BJ, Brady NJ, et al. Cancer Stem Cell Phenotypes in ER Breast Cancer Models Are Promoted by PELP1/AIB1 Complexes. Mol Cancer Res. 2018;16(4):707-719.

Tabbo F, Nottegar A, Guerrera F, Migliore E, Luchini C, Maletta F, et al. Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma. Hum Pathol. 2018;75:167-178.

Baker TM, Rogers W, Chavda KD, Westblade LF, Jenkins SG, Nicolau DP, et al. Epidemiology of Bloodstream Infections Caused by and That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible. Open Forum Infect Dis. 2018;5(12):ofy300.